Every 8-K that Hemab Therapeutics Holdings, Inc. (COAG) has filed with the SEC in the last 24 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 8-K covers material events a company has to report between its quarterly reports, so if you follow COAG and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full COAG filings page.
Hemab Therapeutics Holdings, Inc. (COAG) elected Keli Walbert to its Board effective immediately on September 24, 2026. She will serve as a Class I director through the 2027 annual meeting and join the Audit Committee. Under the company’s non-employee director compensation policy, she will receive annual cash compensation of $40,000 for Board service and an additional $10,000 for Audit Committee service, along with annual equity grants and reimbursement of reasonable travel and out-of-pocket expenses for meetings.
She will be granted an option to purchase 36,000 shares at an exercise price equal to the common stock’s closing price on the Grant Date. The option will vest in equal monthly installments through the third anniversary of the Grant Date, subject to continued service, and vesting will accelerate in full upon a change in control.
Hemab Therapeutics Holdings, Inc. reported second quarter 2026 results, highlighting increased investment in its pipeline and a larger loss. For the quarter ended June 30, 2026, operating expenses were $26,079 thousand, up from $16,057 thousand a year earlier, leading to a net loss of $24,150 thousand versus $12,209 thousand in 2025.
The company strengthened its balance sheet in the first half of 2026, with cash and cash equivalents of $237,366 thousand and marketable securities of $220,094 thousand as of June 30, 2026, and total stockholders’ equity of $454,271 thousand. Net cash provided by financing activities was $317,119 thousand in the first six months.
Pipeline progress included FDA endorsement of the sutacimig data package as sufficient to proceed to a Phase 3 pivotal trial in Glanzmann thrombasthenia, with Phase 3 initiation planned in the second half of 2026. New HMB-002 data showed a ≥2.4-fold increase in Von Willebrand Factor and Factor VIII, and Hemab unveiled HMB-003, a novel peptide-based plasmin inhibitor initially targeting heavy menstrual bleeding.
Hemab Therapeutics Holdings, Inc. furnished its first quarter 2026 results and recent milestones. The company completed an upsized IPO in May 2026, selling 19,262,500 shares at $18.00 per share and raising gross proceeds of $346.7 million, and its stock now trades on the Nasdaq Global Select Market under the symbol COAG.
For the quarter ended March 31, 2026, Hemab reported a net loss of $22.7 million, driven mainly by $19.5 million in research and development and $4.2 million in general and administrative expenses. Cash and cash equivalents were $49.9 million and marketable securities were $113.7 million as of March 31, 2026, supporting its clinical-stage pipeline, including sutacimig and HMB‑002 for rare coagulation disorders.
Hemab Therapeutics Holdings, Inc. reported that Laura Tadvalkar, Ph.D. has resigned from its board of directors, effective May 8, 2026. The company states that her resignation is not related to any disagreement with Hemab on operations, policies, or practices.
Hemab Therapeutics Holdings, Inc. completed its initial public offering of 19,262,500 shares of common stock, including the full underwriter overallotment, at $18.00 per share, generating $346.7 million in gross proceeds before fees.
In connection with the IPO, the company filed a Restated Certificate of Incorporation increasing authorized common stock to 400,000,000 shares, authorizing 5,000,000 shares of undesignated preferred stock, and establishing a classified board with directors removable only for cause by a 75% supermajority vote. The company also adopted amended and restated bylaws that remove stockholder action by written consent, restrict stockholder ability to call special meetings, and add detailed procedures for stockholder proposals and director nominations, along with Delaware and federal exclusive forum provisions.